Brought to you by 
Atairgin, Northwestern U. develop cancer diagnostics
07 Sep 1999
Executive Summary
Northwestern University will use Atairgin Technologies' (reproductive cancer diagnostics and therapeutics) lysophospholipid platform technology to develop for the company an early detection marker for ovarian cancer. Dr. David Fishman, the director of NU's ovarian cancer detection program whose expertise is in bioactive lipids, will carry out the research.
Deal Industry
- Biotechnology
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Atairgin, Northwestern U. develop cancer diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice